Leptomenigeal neoplasms

Current Treatment Options in Neurology

Volumn 9, Issue 4, 2007, Pages 283-293

  Drappatz, Jan ^a   Batchelor, Tracy T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOXYPEPTIDASE; CORTICOSTEROID; CYTARABINE; CYTOKINE; DEXAMETHASONE; DIAZIQUONE; FOLINIC ACID; INTERLEUKIN 2; IODINE 131; MAFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIMETHAMINE; RITUXIMAB; STEROID; THIOTEPA; TOPOTECAN; TRASTUZUMAB; TRIMETHOPRIM;

ACUTE KIDNEY FAILURE; ARACHNOIDITIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN VENTRICLE; BRAIN VENTRICLE PERITONEUM SHUNT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFUSION; DEMENTIA; DIET THERAPY; DISORIENTATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GAIT DISORDER; HUMAN; HYDROCEPHALUS; LEUKEMIA; LEUKOENCEPHALOPATHY; LIFESTYLE MODIFICATION; LIVER TOXICITY; LUMBAR PUNCTURE; LYMPHOMA; MENINGEAL METASTASIS; MENINGITIS; MORBIDITY; MUCOSA INFLAMMATION; MUSCLE STIFFNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PLEOCYTOSIS; POSTOPERATIVE COMPLICATION; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SPEECH THERAPY; SUBARACHNOID SPACE; SURGICAL TECHNIQUE; SYSTEMIC DISEASE;

EID: 34447520017     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-007-0014-5     Document Type: Review

References (46)

1. Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579-592.
2. Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974, 30:122-137.
3. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759-772.
4. Herrlinger U, Forschler H, Kuker W, et al.: Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Set 2004, 223:167-178.
5. Engelhard HH, Corsten LA: Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res 2005, 125:71-85.
6. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ: The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999, 246:810-814.
7. Collie DA, Brush JP, Lammie GA, et al.: Imaging features of leptomeningeal metastases. Clin Radiol 1999, 54:765-771.
8. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38:51-57.
9. Cheng TM, O'Neill BP, Scheithauer BW, Piepgras DG: Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994, 34:590-595; discussion 596.
10. Chamberlain MC: Neoplastic meningitis: a guide to diagnosis and treatment. Curr Opin Neurol 2000, 13:641-648.
11. DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998, 38:245-252.
12. Glantz MJ, Hall WA, Cole BF, et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75:2919-2931.
13. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655-1662.
14. Glantz MJ, Kim L, Choy H, Akerley W: Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology (Williston Park) 1999, 13(Suppl 5):78-82.
15. Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110-3116.
16. Siegal T: Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998, 38:151-157.
17. Boogerd W, Hart AA, van der Sande JJ, Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991, 67:1685-1695.
18. Fizazi K, Asselain B, Vincent-Salomon A, et al.: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996, 77:1315-1323.
19. Lassman AB, Abrey LE, Shah GD, et al.: Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006, 78:255-260.
20. Glantz MJ, Cole BF, Recht L, et al.: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998, 16:1561-1567.
21. Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
22. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993, 11:561-569.
23. Gajjar A, Fouladi M, Walter AW, et al.: Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999, 17:1825-1828.
24. Chamberlain MC, Corey-Bloom J: Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991, 41:1765-1769.
25. Mason WP, Yeh SD, DeAngelis LM: 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998, 50:438-444.
26. Chamberlain MC, Kormanik PA: Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996, 46:1674-1677.
27. Chamberlain MC: Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998, 38:135-140.
28. Mehta M, Bradley K: Radiation therapy for leptomeningeal cancer. Cancer Treat Res 2005, 125:147-158.
29. Hanssens PE, Lagerwaard FJ, Levendag PC: Principles of radiotherapy of neoplastic meningosis. J Neurooncol 1998, 38:145-150.
30. Addeo R, Caraglia M, Faiola V, et al.: Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007, 7:18.
31. Verger E, Gil M, Yaya R, et al.: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61:185-191.
32. Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM: Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005, 64:1625-1627.
33. Sandberg DI, Bilsky MH, Souweidane MM, et al.: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47:49-54; discussion 54-55.
34. Blaney SM, Balis FM, Berg S, et al.: Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23:1555-1563.
35. Gammon DC, Bhatt MS, Tran L, et al.: Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health Syst Pharm 2006, 63:2083-2086.
36. Berg SL, Balis FM, Zimm S, et al.: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143-148.
37. Gururangan S, Petros WP, Poussaint TY, et al.: Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 2006, 12:1540-1546.
38. Rubenstein JL, Fridlyand J, Abrey L, et al.: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350-1356.
39. Stemmler HJ, Schmitt M, Harbeck N, et al.: Application of intrathecal trastuzumab (Herceptin trade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006, 15:1373-1377.
40. Laufman LR, Forsthoefel KF: Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001, 2:235.
41. Platini C, Long J, Walter S: Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006, 7:778-780.
42. Kramer K, Cheung NK, Humm JL, et al.: Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 2000, 35:716-718.
43. Herrlinger U, Weller M, Schabet M: New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998, 38:233-239.
44. Drappatz J, Batchelor T: Leptomeningeal and peripheral nerve metastases. Continuum 2005, 11:47-68.
45. Berg SL, Chamberlain MC: Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 2005, 125:121-146.
46. Balm M, Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996, 53:626-632.